The SSG was formed in 1979 by physicians and scientists from the Scandinavian countries with a primary interest in tumors of connective tissues.
The goal of the SSG is to advance the care of patients with sarcoma and to increase knowledge of all aspects of the biology of these tumors, including basic and clinical research. The SSG has developed treatment protocols for different sarcoma types and participates in international clinical trials.
At this website you can access treatment protocols, find information about previous and future SSG meetings with links to SSG publications.
SSG administrative coordinator: Eva-Mari Olofsson
Email: Eva-Mari.Olofsson@med.lu.se
The Scandinavian Sarcoma Group is a part of Lund University and follows the instructions/regulations for data protection for Lund University.
For more information please, follow this link https://www.lunduniversity.lu.se/about/contact-us/processing-of-personal-data-at-lund-university.
EURAMOS-1: Poor Response Randomisation
The Independent Data Monitoring Committee for EURAMOS-1 has recommended early release and dissemination of the results of the Poor Response randomisation. This proposal was ratified by the Trial Steering Committee.
This comparison investigated the efficacy and safety of an intensified CT regimen for patients (pts) with a “poor response” with a primary outcome measure of event free survival (EFS). 618 patients joined this randomisation from the four trials groups. 300 events have been observed to a target of 378.
The data show that adding ifosfamide and etoposide to MAP is associated with additional morbidity and has no effect on survival outcomes. Evidence from
EURAMOS-1 does not support adaptation of postoperative chemotherapy based on histological response.
The data will be presented in detail at the Connective Tissue Oncology Society Meeting in Berlin on October 17, 2014.